Neuroendocrine Regulation & Pathophysiology of Hypogonadism
Testosterone biosynthesis is tightly controlled by the Hypothalamic-Pituitary-Gonadal (HPG) axis. Hypothalamic GnRH stimulates anterior pituitary secretion of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH), which act on testicular Leydig and Sertoli cells respectively. Disruption anywhere along this axis produces male hypogonadism, requiring precise physiological categorization before initiating hormonal intervention.
Endogenous HPG Signal Cascade
Secretes Gonadotropin-Releasing Hormone (GnRH) into the hypophyseal portal bloodstream.
LH binds Leydig cell receptors for steroidogenesis; FSH stimulates Sertoli cells for spermatogenesis.
Converts cholesterol to testosterone, exerting negative feedback on hypothalamic GnRH and pituitary LH.
5$\alpha$-reductase yields dihydrotestosterone (DHT); aromatase converts T into Estradiol ($E_2$) for bone/brain homeostasis.
Etiological Classification Simulator
Toggle underlying pathology to inspect endocrine feedback markers
Arises from direct testicular parenchymal damage. The pituitary attempts to compensate by secreting high levels of LH and FSH, but damaged Leydig cells cannot produce adequate testosterone. Common causes include cryptorchidism, Klinefelter syndrome, viral orchitis, or surgical orchidectomy. TRT is universally indicated.
Diagnostic Protocols & Reversible Differential Audit
Guidelines from BPACNZ and Medsafe strictly guard against the medicalization of healthy male aging. Diagnostic confirmation requires specific symptoms combined with two separate early-morning serum testosterone measurements, alongside rigorous exclusion of reversible physiological suppressors and psychiatric overlaps.
BPACNZ / Medsafe Diagnostic Checklist & Symptom Audit
Select patient criteria below to evaluate diagnostic validity according to New Zealand best-practice guidelines:
Complete the clinical audit checklist above. Diagnosis requires specific clinical symptoms, two morning serum tests on separate days, and exclusion of reversible suppressors.
Psychiatric Overlap & Reversible Suppressors
Depression mirrors hypogonadism via fatigue, low mood, and loss of libido. Treating depression directly often resolves perceived androgen deficiency symptoms without hormonal risks.
Selective Serotonin Reuptake Inhibitors (SSRIs) directly induce delayed ejaculation and suppressed libido independent of testosterone levels. Antihypertensives (e.g., spironolactone) exert anti-androgenic effects.
High-dose opioids suppress hypothalamic GnRH pulsatility, causing profound secondary hypogonadism that typically reverses upon analgesic tapering.
Pharmacokinetics & NZ Formulation Profiles
Native testosterone undergoes complete first-pass hepatic degradation when ingested orally. To achieve systemic bioactivity, formulations utilize esterification in lipophilic oil vectors or hydroalcoholic transdermal gels. In New Zealand, four primary delivery modalities are available under Pharmac funding rules.
Serum Concentration Profiles (12-Week Timeline)
Compare daily steady state gels vs volatile Sustanon waves and Reandron depots
NZ Pharmac-Funded Armamentarium
Starting Dose: 40.5 mg (2 pump actuations). Max: 81 mg (4 pumps). Applied to upper arms/shoulders. Wait 1 hour before showering.
⚠️ Strict hygiene: Avoid secondary transfer to women/children.Dose: 1000 mg / 4 mL. Long-acting 11-carbon lipophilic ester depot. Requires 6-week loading interval. Deep IM injection only.
Dose: 100 mg/mL (50–400 mg). 8-carbon ester with benzyl alcohol. Amenable to self-administration via IM or SubQ routes.
Dose: 250 mg / 1 mL glass ampoule. Blend of 4 esters (propionate, phenylpropionate, isocaproate, decanoate). High kinetic volatility.
Clinical Procedural Guidelines & POME Etiology
Administering viscous oily formulations into skeletal muscle requires strict biomechanical execution according to PATHA guidelines. Rapid, forceful delivery creates high hydrostatic pressure, risking microvascular rupture and Pulmonary Oil Microembolism (POME).
Intramuscular Injection Protocol (PATHA)
Pulmonary Oil Microembolism (POME) Etiology & Simulator
Complication RiskAdjust injection administration speed below to simulate hydrostatic pressure and pulmonary microvascular risk:
Rapid injection forces dense oily solution into local capillaries under massive hydrostatic pressure. Droplets travel through systemic veins into the pulmonary capillary bed, causing immediate microembolisms. Strictly enforce the 4-minute injection rule.
Systemic Pharmacovigilance & Therapeutic Timelines
Exogenous testosterone exerts profound systemic physiological effects. While restoring vitality, therapy requires lifelong surveillance of hematological, cardiovascular, and prostatic parameters. Therapeutic response exhibits a distinct temporal dichotomy between psychological benefits and structural tissue adaptations.
Therapeutic Timeline: Onset of Physiological Benefits
Subjective psychological benefits manifest in weeks; structural remodeling requires up to 12 months.
Systemic Risk Parameters
Testosterone stimulates renal erythropoietin production. Hematocrit > 0.50 L/L significantly elevates whole-blood viscosity and thrombosis risk. Requires dose reduction or phlebotomy.
NZ MARC (2014) confirmed no causal MACE link at physiological replacement doses. However, VTE (DVT/PE) risk requires vigilance in thrombophilic patients.
TRT does not cause de novo prostate cancer, but accelerates pre-existing carcinomas. Strictly contraindicated in active prostate cancer. Requires yearly DRE/PSA testing.
Exogenous T suppresses LH/FSH, shutting down intratesticular testosterone and arresting spermatogenesis. Must discuss fertility desires prior to starting.
NZ Healthcare Access Pathways & Regulatory Framework
Testosterone is a Class B/Controlled Prescription Medicine under the New Zealand Medicines Act 1981. While fully funded under Pharmac without Special Authority restrictions for primary injectables, navigating clinical access involves distinct primary, secondary, private, and regulatory pathways.